CureVac - Hauptforum Forum: Community User: NeulingImDAX

Der ganze Ablauf erinnert schon stark an Wirecard. Andauernde Verschiebungen, große Versprechungen, schlechte Kommunikation, schlechte Ergebnisse. Nein, CureVac wird nicht pleite gehen. Aber das Management ist eine Katastrophe. Sehr sehr schade! Ich hätte es den Mitarbeitern und Forschern, die hart gearbeitet haben, gegönnt. Den CEO kann man allerdings in der Pfeife rauchen.

Warum wird hier Rudiii angegriffen...er hat so viel Zeit investiert...das Drama konnte keiner ahnen..wobei ich noch an positiven Ende glaube

Chief technical officer Mariola Fotin-Mleczek told the FT that one of the variants, the Lambda strain first detected in Peru, made up 21 per cent of infections but was still so unknown there was very little information on it. “This is not available because it’s really new,” she said. “And if you ask different labs, nobody’s heard about this.” As with the Moderna and Pfizer vaccines, CureVac’s jab uses messenger ribonucleic acid, but its mRNA is unmodified and uses lower doses — 12 microgrammes compared with Moderna’s 100mcg and Pfizer’s 30mcg. This would result in a lower cost of production and be stable at conventional fridge temperatures. Fotin-Mleczek declined to speculate on whether the interim findings suggested low doses were not as viable, citing the variants as a bigger factor and the fact that initial studies of its second-generation vaccine were still promising. Early data show an increase of up to tenfold in immune response compared with the first-generation treatment. CureVac and GSK aim to make the jab available in 2022.

Jetzt stellt euch mal vor..ihr werd jetzt nicht in curevac involviert, würdet ihr jetzt investieren? Denn genau das macht ihr gerade..ihr investiert gerade in curevac.. kapiert ihr es nicht?

CureVac’s chief financial officer said the company had not given up on its coronavirus vaccine, despite disappointing results from trials, with hope remaining that the jab might be targeted at some parts of the population. Interim findings from its late-stage trial suggest the vaccine has only 47 per cent efficacy, but Pierre Kemula said the company still believed a final analysis could confirm the jab could be offered to certain age groups or as a booster. “There is a lot of need for vaccine out there,” Kemula told the ---------------on Thursday. “We will define [ . . .] hand in hand with the agencies where the sweet spot of the vaccine is.” Early on in the pandemic, Europe had pinned high hopes on CureVac, based in the south-western German city of Tübingen. Germany bought 23 per cent of the company to stave off concerns it could move to the US. But since then it has fallen behind other producers of mRNA vaccine,. The latest data come from a study of 40,000 people in 10 countries across Latin America and Europe, and CureVac argues that its results cannot be compared to other vaccine producers who did not come up against as many variants. Kemula said CureVac was not willing to drop its treatment without sifting through the completed data from the final study, which will analyse 200 cases of coronavirus contracted in the trial. But real-world evidence and lab studies from other big vaccine makers suggest their jabs have handled variants better than CureVac’s. CureVac had aimed to produce 300m doses of its vaccine this year and 1bn in 2022, and had a partnership with Bayer to do so. Shares in the group, which investors have raced to back since it listed on Wall Street in August 2020, plunged as much as 50 per cent on Thursday after the company released the data late on Wednesday. Although the trial results throw the viability of those projects into doubt, they are not necessarily bad news for a next-generation vaccine it is developing with GlaxoSmithKline aimed at tackling variants. But Kemula said the company at this stage was not considering dropping its first candidate drug to focus on the second. “We are so close. We are two-three weeks away from final data . . . If we have something, then, of course, we will leverage it,” he said. “We need to look at the data and see, OK, what would be the best value, how we can place this vaccine to make this available.”

Leute an was glaubt ihr. Alles hinhaltetaktik

Erhardt, genauso ist es..das ist geplante , systematische Vera rsche vom allerfeinsten

Da hast du recht Erhard

Pfizer -Biontech-Moderna dont have the access - suspect they will continue relying on Biden DPA export ban PRESSEMITTEILUNG 5. Februar 2021 CureVac kooperiert mit britischer Regierung bei der Entwicklung von Impfstoffen gegen SARS-CoV-2-Varianten https://www.curevac.com/2021/02/05/curevac-kooperiert-mit-britischer-regierung-bei-der-entwicklung-von-impfstoffen-gegen-sars-cov-2-varianten/

Die entscheidende Frage ist doch, wer will sich noch freiwillig mit CureVac impfen lassen, bei den klar besseren Alternativen? Auch mit (unwahrscheinlicher) Zulassung kein Geschäft! No invest!

Würde mich nicht wundern wenn Curevac Morgen nach Auswertung der Zwischenergebnisse was positives vorm WE verkünden

Curevac Verteidiger ja, aber ich lasse mich nicht gerne verarschen. So etwas in der Nacht bekannt zu geben ist eine große Sauerei.

Weil Erhardt ein normal vernünftig denkender Mensch ist, der weiß, wann es vorbei ist

seven21075, ich warne schon seit den andauernden Verschiebungen. Aber man will ja nicht hören.

Erhardt war doch sonst immer ein Curevac Verteidiger der jedwede Kritik sofort gebasht hat. Woher jetzt dieser Sinneswandel

Pimp, tu das, bekehre sie in ihrem Glauben 😂